52,478 Shares in Compass Therapeutics, Inc. $CMPX Bought by Walleye Capital LLC

Walleye Capital LLC bought a new position in Compass Therapeutics, Inc. (NASDAQ:CMPX) during the first quarter, according to the company in its most recent filing with the SEC. The firm bought 52,478 shares of the company’s stock, valued at approximately $100,000.

Other large investors also recently added to or reduced their stakes in the company. Wellington Management Group LLP purchased a new position in shares of Compass Therapeutics in the first quarter valued at about $423,000. American Century Companies Inc. purchased a new position in shares of Compass Therapeutics in the first quarter valued at about $140,000. Nuveen LLC purchased a new position in shares of Compass Therapeutics in the first quarter valued at about $579,000. Deutsche Bank AG purchased a new position in shares of Compass Therapeutics in the first quarter valued at about $194,000. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Compass Therapeutics by 4.1% in the first quarter. Charles Schwab Investment Management Inc. now owns 297,880 shares of the company’s stock valued at $566,000 after acquiring an additional 11,689 shares during the period. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Price Performance

Shares of NASDAQ CMPX opened at $3.44 on Friday. Compass Therapeutics, Inc. has a 1 year low of $1.27 and a 1 year high of $4.08. The company’s 50-day moving average is $3.01 and its 200 day moving average is $2.48. The stock has a market capitalization of $475.68 million, a P/E ratio of -7.64 and a beta of 1.50.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.01). Research analysts anticipate that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CMPX has been the topic of a number of analyst reports. Guggenheim boosted their price objective on shares of Compass Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Tuesday, August 12th. Raymond James Financial upgraded shares of Compass Therapeutics to an “outperform” rating and set a $9.00 price objective on the stock in a research report on Tuesday, July 1st. Finally, D. Boral Capital restated a “buy” rating and issued a $32.00 price objective on shares of Compass Therapeutics in a research report on Tuesday, August 12th. One analyst has rated the stock with a Strong Buy rating and nine have given a Buy rating to the stock. According to data from MarketBeat, Compass Therapeutics presently has an average rating of “Buy” and a consensus price target of $12.89.

Compass Therapeutics Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.